People · Operator
Named in public records as an officer, director or promoter · active 2010–2010 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| LeukoDx, Inc. | — | Biotechnology | Series A | $5.7M | $180.8M | 2010 |
Marvin Slepian at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Marvin Slepian on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Bruce Sholk | 1 | 2 |
| Nir Nimrodi | 1 | 2 |
| Mark Chess | 1 | 2 |
| Michael Reynier | 1 | 2 |
| Barry Zubrow | 1 | 1 |
| Charles Piazza | 1 | 1 |
| Julien Meissonnier | 1 | 1 |
| Steve Hurvitz | 1 | 1 |
| Walter Drimer | 1 | 1 |
| Harvey Kasdan | 1 | 1 |
| Bruce Davis | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.